A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 848
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : CMML
Long Form : chronic myelomonocytic leukemia
No. Year Title Co-occurring Abbreviation
2021 A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. HR
2021 A rare cause of acute kidney injury with chronic myelomonocytic leukemia. AKI
2021 Atypical cutaneous histiocytic eruption in a patient with chronic myelomonocytic leukemia: A case report. ---
2021 Autoimmune Complications in Hematologic Neoplasms. AICy, AID, AIHA, CLL, ITP, MDS
2021 Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/β-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes. BMMSCs, HMAs, HSPCs, MDS, MPNs
2021 CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1. Cbl, PI3K, PIK3R1
2021 Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. C-DEC, CDA, FDA, HMAs, MDS
2021 Chronic myelomonocytic leukemia diagnosis and management. AML, CPSS, GFM, HMAs, MDS/MPN, WHO
2021 Chronic myelomonocytic leukemia-associated pulmonary alveolar proteinosis: A case report and review of literature. PAP
10  2021 Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. ITP, IVIG, MDS
11  2021 Common clonal origin of chronic myelomonocytic leukemia and B cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant. B-ALL, FHA, MDS, WES
12  2021 Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia. HMAs
13  2021 CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. ---
14  2021 Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. CCR2, Cytl1, MAPK, MCL1
15  2021 Diagnosis and treatment of chronic myelomonocytic leukemia. ---
16  2021 Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukemia. ABCMML, PB
17  2021 Kidney Involvement in Patients With Chronic Myelomonocytic Leukemia or BCR-ABL-Negative Myeloproliferative Neoplasms. AKI, CKD, ET, MPNs, PV
18  2021 Micro-RNA-125a mediates the effects of hypomethylating agents in chronic myelomonocytic leukemia. AZA, DEC, HMAs, HSPCs, miRs
19  2021 Mutations in chronic myelomonocytic leukemia and their prognostic relevance. AML, MDS, MPN
20  2021 Myeloid Disease with the CSF3R T618I Mutation after CLL. CLL, CNL
21  2021 Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival. ---
22  2021 Non-small-cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy. NGS, NSCLC
23  2021 Novel therapeutic targets for chronic myelomonocytic leukemia. ---
24  2021 Occurrence of a Clonal T-Cell Population in a Case of Chronic Myelomonocytic Leukemia. LPD, MDS, MPN, PCR
25  2021 Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia. LSC, sAML
26  2021 Prognostic assessment for chronic myelomonocytic leukemia in the context of the World Health Organization 2016 proposal: a multicenter study of 280 patients. OS
27  2021 Real-world data of chronic myelomonocytic leukemia: A chinese single-center retrospective study. allo-SCT, CPSS, HMAs, ORR
28  2021 Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). allo-HCT, HMA, LR, MDS
29  2021 Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia. C-DEC, DEC, MDS
30  2021 The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib. AML, PI3K
31  2021 Treatment advances for pediatric and adult onset neoplasms with monocytosis. HMAs, JMML, MDS
32  2021 Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemia. IFN
33  2021 Vascular Notch Signaling in Stress Hematopoiesis. HSCs, T-ALL
34  2020 ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms. ---
35  2020 Acquired Pure Red Cell Aplasia Associated with Chronic Myelomonocytic Leukemia: Too Many of One, Not Enough of the Other. ---
36  2020 Autoimmune disease in CMML-the chicken or the egg? SIADs
37  2020 Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach. CTA, MDS
38  2020 Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome. ---
39  2020 Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report. ---
40  2020 Chronic myelomonocytic leukemia - a review. ---
41  2020 Chronic Myelomonocytic Leukemia Presenting With Polyserositis and Seropositivity for Rheumatoid Arthritis. SAID
42  2020 Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype. MPN, OS, PV
43  2020 Concordance among hematopathologists in classifying blasts plus promonocytes: A bone marrow pathology group study. AML, BM, NSE, PB, WHO
44  2020 Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients. AML
45  2020 Curcumin augments therapeutic efficacy of TRAIL-based immunotoxins in leukemia. ALL, AML, CLL, PBMCs
46  2020 Cytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico. ---
47  2020 Decitabine/Cedazuridine: First Approval. AML, FDC, MDS
48  2020 Donor cell-derived chronic myelomonocytic leukemia presenting after allogeneic hematopoietic cell transplantation for T-cell acute lymphoblastic leukemia. allo-HCT
49  2020 Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. MN1
50  2020 Emerging drugs for the treatment of chronic myelomonocytic leukemia. ---
51  2020 Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. aCML, JMML, MDS, MDS-RS, MPN
52  2020 High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience. AML, CNI, GVHD, MMF, MTX, OS, TBI, UD
53  2020 Improving the accuracy of prognostication in chronic myelomonocytic leukemia. AML, CPSS
54  2020 Incorporating flow cytometry and next-generation sequencing in the diagnosis of CMML. Are we ready for prime? ---
55  2020 Indeterminate Dendritic Cell Tumor as Cutaneous Involvement of Chronic Myelomonocytic Leukemia Successfully Treated With Phototherapy. IDCT
56  2020 LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents. HMA, MDS
57  2020 Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. allo-HCT, CPSS
58  2020 Molecular Basis and Clinical Application of Growth-Factor-Independent In Vitro Myeloid Colony Formation in Chronic Myelomonocytic Leukemia. CFU-GM
59  2020 Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms. ---
60  2020 Monocyte subsets to differentiate chronic myelomonocytic leukemia from reactive monocytosis. ---
61  2020 Moving towards a uniform risk stratification system in CMML - How far are we? CPSS
62  2020 Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review. aCML, JMML, MDS, MPN
63  2020 Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management. CCUS, CHIP, CMUS, ICUS, MDS, sAML
64  2020 Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features. MDSs, OM-CMML
65  2020 Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. FDC, LINE-1, LSM, MDS
66  2020 Outcome and Risk Factors for Therapy-Related Myeloid Neoplasms Treated with Allogeneic Stem Cell Transplantation in Japan. AML, CI, HCT, MDS, t-MN
67  2020 Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. AML, BPDCN, cDCs, pDCs
68  2020 Probable catastrophic antiphospholipid syndrome secondary to chronic myelomonocytic leukaemia in an adult patient and a mini review. APS, CAPS
69  2020 Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study. CCI, CPSS, HCT-CI, IPSS-R, MDAPS, MDS-CI
70  2020 Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: Results of a phase 1 study. AML, MDS
71  2020 Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation. HSPCs
72  2020 Successful long-term treatment with azacitidine in patient with chronic myelomonocytic leukemia. ---
73  2020 Targeting Bim via a lncRNA Morrbid Regulates the Survival of Preleukemic and Leukemic Cells. AML, MPN
74  2020 Temporal artery biopsy for suspected giant cell arteritis: a retrospective analysis. GCA, LVV, PMR, TAB
75  2020 The clinical and pathological panoply of systemic mastocytosis. ASM, SM-AHN
76  2020 The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies. ALL, CBMF, FPD/AML, MDS, MPN
77  2020 Transformation of CMML to AML presenting with acute kidney injury. AML, CT
78  2020 Update on CML-Like Disorders. aCML, CEL-NOS, CML, CNL, MDS/MPN, SM-AHN
79  2020 Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction. IL-6R, PO-MMLR
80  2020 Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study. DMARDs, GCs, IPSS/CPSS, MDS
81  2020 Venetoclax/decitabine for a pediatric patient with chronic myelomonocytic leukemia. DI, HSCT, MDS
82  2020 [Expression and Significance of BTLA and Its Ligand HVEM in Patients with Chronic Myelomonocytic Leukemia]. BTLA
83  2020 [Impact of splenomegaly on outcomes of allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia]. aGVHD, allo-HSCT, cGVHD, GVHD
84  2020 [Polymyalgia rheumatic and chronic myelomonocytic leukemia]. MDS
85  2019 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes. AZA, MDS, NGS
86  2019 A Case of Acquired Haemophilia A in a Patient with Chronic Myelomonocytic Leukaemia. AHA, AZA, FVIII
87  2019 A hierarchical approach in the diagnostic workflow of chronic myelomonocytic leukemia: Pivotal role of the "Mono-dysplasia-score" combined with flow cytometric quantification of monocyte subsets. ---
88  2019 A medical mirroring: chronic myelomonocytic leukemia mimicking immunoglobulin G4-related disease. IgG4-RD
89  2019 A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. AML, EORTC, HR, LB, MDS, PRO
90  2019 A systematic review and meta-analysis of the efficacy and adverse events of azacitidine-plus-lenalidomide treatment for patients with acute myeloid leukemia, myelodysplastic syndromes and chronic myelomonocytic leukemia 1. AML, AZA, CI, CR, LEN, MDS, ORR
91  2019 Advances in chronic myelomonocytic leukemia and future prospects: Lessons learned from precision genomics. ---
92  2019 Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies. AML, APE1, MDS
93  2019 Autoinflammatory constrictive pericarditis and chronic myelomonocytic leukaemia: when one speciality is not enough. ---
94  2019 Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Flt3L, pDCs
95  2019 Chronic myelomonocytic leukemia as a transformation from polycythemia vera. AMC, PV
96  2019 Chronic myelomonocytic leukemia associated with myeloid sarcomas and NPM1 mutation: a case report and literature review. AML
97  2019 Chronic myelomonocytic leukemia with ETV6-ABL1 rearrangement and SMC1A mutation. ---
98  2019 Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment. BMT, HMAs, MDS, MPNs
99  2019 Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. CPSS-Mol, GFM, MMM
100  2019 Chronic Myelomonocytic Leukemia: Insights into Biology, Prognostic Factors, and Treatment. ---